If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
75
results.
Updated on
21/02/2026 [07:36:00]
Absstract of: US20260048090A1
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.
Absstract of: AU2026200694A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies. an a n
Absstract of: US20260048083A1
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Absstract of: EP4697021A2
An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.
Absstract of: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Absstract of: CN120187864A
The present invention relates to neurodegenerative diseases, and to the diagnosis and/or prognosis of neurodegenerative diseases in test subjects using lateral flow testing or the like. The invention also relates to the detection of diagnostic and prognostic biomarkers in a variety of patient sample types for the diagnosis and/or prognosis of neurodegenerative diseases, such as Alzheimer's disease. The invention also provides biomarker detection methods and devices for diagnosis and prognosis of neurodegenerative diseases and methods of treating patients diagnosed or prognosed with neurodegenerative diseases. The invention also extends to detection of biomarkers and/or screening in subjects before symptoms for early diagnosis, so that diseases can be prevented or intervened.
Absstract of: WO2024166074A1
The present invention relates to a method of isolating exosomes from human immature dental pulp stem cell (hIDPSC) cultures that is scalable. The present invention also provides pharmaceutical compositions comprising exosomes and methods of using these pharmaceutical compositions to treat a neurological disease or condition, infectious disease, or cancer.
Absstract of: WO2026033422A1
Provided herein is a method of identifying a pre-stage neurofibrillary tangle (NFT) in a patient sample, including obtaining a sample from a patient suspected of having or at risk of developing a tauopathy, incubating the sample with a composition comprising a first binding reagent, wherein the first binding reagent is specific to Ser262 and/or Ser356 of a tau protein, and detecting binding between the first binding reagent and the tau protein, wherein detecting binding between the first binding reagent and the tau protein indicates the presence of a pre-stage NFT in the patient sample.
Absstract of: WO2026035942A1
The present invention provides novel compositions and methods for treating diseases and conditions associated with amyloid beta in a subject, said method comprising administering to the subject (i) an anti-amyloid beta antibody or an antigen binding fragment thereof and (ii) a regulatory T cell (Treg) inducing or activating agent.
Absstract of: US20260043791A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Absstract of: US20260043816A1
TDP-43 binding molecules specifically binding phosphorylated TDP-43 are provided, together with the nucleic acid molecules that encode the binding molecules. These binding molecules are useful in diagnostic and therapeutic applications and may be included in suitable compositions and kits. They may be used in pairing assays involving use of capture and detect antibody pairs. They may be used to monitor diseases associated with TDP-43, including for testing candidate therapeutic agents.
Absstract of: AU2024291458A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.
Absstract of: US20260034143A1
Compositions of Allopregnanolone (Allo), and methods of use thereof for treating and preventing Alzheimer's Disease (AD) or dementia have been developed. In some embodiments, the amount of Allo effective to treat AD or dementia is between about 2 mg and about 10 mg, preferably 4 mg per dose. Methods for identifying subjects for treatment of AD or dementia are also provided. The methods include selecting a subject having one or more Apo E4 gene alleles. Methods of treating a human subject having AD or at risk of AD OR DEMENTIA are provided. The methods include administering a dosage of from 2 mg to 6 mg to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently. The methods stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes.
Absstract of: AU2024291458A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.
Absstract of: WO2026030628A2
Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.
Absstract of: WO2026027796A1
The present invention relates to peptides, in particular of amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides, for use in methods of treating or preventing or delaying the onset of synucleinopathies, in particular of Parkinson's disease (PD) or dementia with Lewy bodies, and their comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD). Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of diagnosing such synucleinopathies and related comorbidities. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of synucleinopathies and related comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD), in a patient.
Absstract of: US20260035756A1
The present invention relates to methods and kits for the collection, preservation and storage of analytes of interest present in biological test samples (biofluid samples). In particular, the present invention relates to means to collect the biological test sample such that substantially all pathogen present in the biological test sample is inactivated, while preserving the analyte of interest in a format to allow subsequent analysis.
Absstract of: US20260034088A1
Provided herein is the use of a compound of Formula I:or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Absstract of: EP4686725A1
The present invention relates to peptides, in particular of amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides, for use in methods of treating or preventing or delaying the onset of synucleinopathies, in particular of Parkinson's disease (PD) or dementia with Lewy bodies, and their comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD). Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of diagnosing such synucleinopathies and related comorbidities. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of synucleinopathies and related comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD), in a patient.
Absstract of: CN120457337A
The present disclosure provides a method of preparing a biosensor for detecting Alzheimer's disease biomarkers, comprising depositing an alumina film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing an electric contact part Cr/Au on the Al2O3/Si substrate through a thermal evaporator, and forming a source electrode, a drain electrode and a planar grid electrode on the Al2O3/Si substrate; providing double-layer graphene on the Al2O3/Si substrate through thermal annealing in a vacuum environment; performing low-damage plasma treatment (LDPT) on the double-layer graphene with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite material on the Al2O3/Si substrate; an antibody is immobilized on the surface of a GO/G layered composite material by a reaction between an amine group of the antibody and a carboxyl group of GO of the GO/G layered composite material, where the antibody is specific for p-tau217 protein.
Absstract of: JP2025118826A
To provide methods and compositions useful for diagnosis of AD, as well as methods and compositions useful for indicating therapeutic efficacy of an agent for treating AD.SOLUTION: A method for determining whether a subject has an increased risk of subsequently developing AD is provided, the method comprising: (1) comparing the subject's plasma, serum, or whole blood level or concentration of any one protein selected from Tables 1-4 with a standard control level of the same protein found in the plasma, serum, or whole blood of an average healthy subject not suffering from or at increased risk for AD; (2) detecting that the subject's plasma, serum, or whole blood level of the protein having a positive β value or a negative β value in Table 1, 2, 3, or 4 is higher or lower than the standard control level; and (3) determining that the subject has an increased risk for AD.SELECTED DRAWING: Figure 1
Absstract of: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Absstract of: US20260029414A1
A bioassay system for multiplexed detection and quantification of multiple analytes (e.g., Aβ40, Aβ42, pTau181, p217Tau, GFAP, and NFL) in a biological sample is provided. The bioassay system includes a plurality of sets of color-coded microspheres. Each set of microspheres is distinguishable by a unique color code generated by internal dyes. The bioassay system includes a first set of control microspheres attached to mouse polyclonal IgG to correct for a background of individual specimens and a second set of control microspheres configured to capture a synthetic peptide to normalize for well-to-well variations. Bioassay system also includes a fluidic system configured to mix the sample with the plurality of sets of color-coded microspheres to allow for specific binding between analytes and their corresponding capture agent among other analytes and a detection system for exciting and reading fluorescence of the internal dyes and a reporter fluorescence indicative of analyte binding.
Absstract of: WO2026022191A1
The present invention relates to the field of neurodegenerative diseases, in particular Alzheimer's disease. The present invention further relates to fibrillary Apolipoprotein E (ApoE) for use in a method of treatment and/or prevention of a neurodegenerative disease and methods of producing said fibrillary ApoE. Moreover, the present invention relates to an antigen-binding peptide specifically binding to fibrillary ApoE, preferably human ApoE, a method of generating said antigen-binding peptide, and its use in a method of treatment and/or prevention and/or diagnosis of a neurodegenerative disease in a patient in need thereof.
Nº publicación: EP4685158A1 28/01/2026
Applicant:
UNIV MUENCHEN TECH [DE]
Technische Universit\u00E4t M\u00FCnchen
Absstract of: EP4685158A1
The present invention relates to the field of neurodegenerative diseases, in particular Alzheimer's disease. The present invention further relates to fibrillary Apolipoprotein E (ApoE) for use in a method of treatment and/or prevention of a neurodegenerative disease and methods of producing said fibrillary ApoE. Moreover, the present invention relates to an antigen-binding peptide specifically binding to fibrillary ApoE, preferably human ApoE, a method of generating said antigen-binding peptide, and its use in a method of treatment and/or prevention and/or diagnosis of a neurodegenerative disease in a patient in need thereof.
BOPI
Electronic site
